Shengtao Xu

Prof. Dr. Shengtao Xu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2016 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
HYHong Yao
Hong Yao
JLJunkai Liu
Junkai Liu
SXShengtao Xu
Shengtao Xu
ZZZheying Zhu
Zheying Zhu
JXJinyi Xu
Jinyi Xu
Introduction: Throughout history, natural products (NPs) have provided a rich source of compounds that have wide applications in the fields of medicine, health sciences, pharmacy and biology. Although naturally active substances are good lead compounds for the discovery of new drugs, most of them suffer from various deficiencies or shortcomings, such as complex structures, poor stability and solubility. Therefore, structural modification of NPs is needed to develop novel compounds with specific properties. Areas covered: This article presents an overview on the structural modifications of NPs in drug development. The application of multiple classes of NPs to the treatment of conditions such as cancers, infection, Alzheimer’s and diabetes are discussed. This article also reveals that modification of NPs is a versatile approach to explore their mode of actions, which may lead to the discovery of novel drugs. Expert opinion: NPs are usually described by structural diversity and complexity. The use of isolated NPs as scaffolds for modification is a good approach to drug discovery and development. Despite many limitations associated with NPs, the total synthesis, semisynthetic modification, SAR-based modification, sometimes even a single atom alteration, may lead to the discovery of a novel drug.

1 August 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PZPengfei Zhang
Pengfei Zhang
SXShengtao Xu
Shengtao Xu
ZZZheying Zhu
Zheying Zhu
JXJinyi Xu
Jinyi Xu

3 August 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SXShaowen Xie
Shaowen Xie
JZJingjie Zhu
Jingjie Zhu
JLJunda Li
Junda Li
FZFeiyan Zhan
Feiyan Zhan
HYHong Yao
Hong Yao
SXShengtao Xu
Shengtao Xu

1 February 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WLWenlong Li
Wenlong Li
WSWen Shuai
Wen Shuai
HSHonghao Sun
Honghao Sun
FXFeijie Xu
Feijie Xu
YBYi Bi
Yi Bi
SXShengtao Xu
Shengtao Xu

Verified
Journal Article
Open access
PDF file
DLDahong Li
Dahong Li
THTong Han
Tong Han
JLJie Liao
Jie Liao
XHXu Hu
Xu Hu
SXShengtao Xu
Shengtao Xu
JXJinyi Xu
Jinyi Xu
Oridonin belongs to ent-kaurane tetracyclic diterpenoid and was first isolated from Isodon species. It exhibits inhibitory activities against a variety of tumor cells, and pharmacological study shows that oridonin could inhibit cell proliferation, DNA, RNA and protein synthesis of cancer cells, induce apoptosis and exhibit an antimutagenic effect. In addition, the large amount of the commercially-available supply is also very important for the natural lead oridonin. Moreover, the good stability, suitable molecular weight and drug-like property guarantee its further generation of a natural-like compound library. Oridonin has become the hot molecule in recent years, and from the year 2010, more than 200 publications can be found. In this review, we summarize the synthetic medicinal chemistry work of oridonin from the first publication 40 years ago and share our research experience of oridonin for about 10 years, which may provide useful information to those who are interested in this research field.

23 May 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HYHong Yao
Hong Yao
GUGiuseppe Uras
Giuseppe Uras
PZPengfei Zhang
Pengfei Zhang
SXShengtao Xu
Shengtao Xu
YYYing Yin
Ying Yin
JXJinyi Xu
Jinyi Xu